만성 및/또는 아급성 피부 홍반루푸스 성인을 대상으로 아니프롤루맙의 유효성과 안전성을 조사하기 위한 연구 (LAVENDER)
항말라리아 치료에 불응성 및/또는 불내성인 만성 및/또는 아급성 피부홍반루푸스 성인을 대상으로 아니프루맙의 효능과 안전성을 평가하기 위한 다기관, 무작위, 이중 맹검, 위약 대조, 제3상 연구
This study aims to evaluate the efficacy and safety of subcutaneous (SC) anifrolumab versus placebo in adult participants with chronic and/or subacute cutaneous lupus erythematosus (CLE).
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
This is a multicenter, randomized, double-blind, placebo-controlled, Phase III study to evaluate the efficacy and safety of anifrolumab in adults with chronic and/or subacute CLE who are refractory and/or intolerant to antimalarial therapy. The study has a randomized, 24-week double-blind, placebo-controlled study period (Week 0 to Week 23), to evaluate the efficacy and safety of anifrolumab. The double-blind study period will be followed by an open-label, uncontrolled treatment period in which all participants will receive treatment with anifrolumab from Week 24 to Week 51. After the open-label treatment period, participants will enter a 12-week Safety Follow-up Period.
연구 유형
연구 유형
등록 (실제)
등록
단계
단계
- 3단계
연락처 및 위치
연구 장소
-
-
-
Athens, 그리스, 12462
- Research Site
-
Athens, 그리스, 16121
- Research Site
-
-
-
-
-
Cape Town, 남아프리카, 7500
- Research Site
-
Johannesburg, 남아프리카, 2193
- Research Site
-
-
-
-
-
Breda, 네덜란드, 4818 CK
- Research Site
-
Rotterdam, 네덜란드, 3015 GD
- Research Site
-
-
-
-
-
Papatoetoe, 뉴질랜드, 2025
- Research Site
-
-
-
-
-
Kaohsiung City, 대만, 83301
- Research Site
-
Taichung, 대만, 404
- Research Site
-
Taipei, 대만, 10449
- Research Site
-
-
-
-
-
Seoul, 대한민국, 03080
- Research Site
-
Seoul, 대한민국, 06591
- Research Site
-
Seoul, 대한민국, 06973
- Research Site
-
-
-
-
-
Aarhus, 덴마크, 641-8510
- Research Site
-
Copenhagen, 덴마크, 2100
- Research Site
-
-
-
-
-
Berlin, 독일, 10117
- Research Site
-
Bochum, 독일, 44791
- Research Site
-
Dresden, 독일, 01307
- Research Site
-
Erlangen, 독일, 91054
- Research Site
-
Essen, 독일, 45147
- Research Site
-
Freiburg im Breisgau, 독일, 79104
- Research Site
-
Hanover, 독일, 30625
- Research Site
-
Kiel, 독일, 24105
- Research Site
-
Leipzig, 독일, 04103
- Research Site
-
Mainz, 독일, 55131
- Research Site
-
Marburg, 독일, 35043
- Research Site
-
Regensburg, 독일, 93053
- Research Site
-
Wuppertal, 독일, 42283
- Research Site
-
-
-
-
-
Bucharest, 루마니아, 020125
- Research Site
-
Iași, 루마니아, 700291
- Research Site
-
-
-
-
-
Guadalajara, 멕시코, 44340
- Research Site
-
Guadalajara, 멕시코, 44610
- Research Site
-
Mexico City, 멕시코, 07760
- Research Site
-
Veracruz, 멕시코, 91910
- Research Site
-
-
-
-
Arizona
-
Phoenix, Arizona, 미국, 85028
- Research Site
-
-
California
-
Covina, California, 미국, 91722
- Research Site
-
La Jolla, California, 미국, 92037
- Research Site
-
Los Angeles, California, 미국, 90045
- Research Site
-
Los Angeles, California, 미국, 90089
- Research Site
-
Orange, California, 미국, 92868
- Research Site
-
San Francisco, California, 미국, 94143
- Research Site
-
-
Colorado
-
Aurora, Colorado, 미국, 80045
- Research Site
-
-
Connecticut
-
New Haven, Connecticut, 미국, 06519
- Research Site
-
-
District of Columbia
-
Washington D.C., District of Columbia, 미국, 20037
- Research Site
-
-
Florida
-
Fort Lauderdale, Florida, 미국, 33309
- Research Site
-
Miami, Florida, 미국, 33174
- Research Site
-
Plantation, Florida, 미국, 33324
- Research Site
-
-
Illinois
-
Chicago, Illinois, 미국, 60637
- Research Site
-
Chicago, Illinois, 미국, 60611
- Research Site
-
-
Indiana
-
Indianapolis, Indiana, 미국, 46202
- Research Site
-
-
Maryland
-
Baltimore, Maryland, 미국, 21287
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02114
- Research Site
-
Boston, Massachusetts, 미국, 02115-5817
- Research Site
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48109
- Research Site
-
Bloomfield Hills, Michigan, 미국, 48302
- Research Site
-
-
Minnesota
-
Rochester, Minnesota, 미국, 55905
- Research Site
-
-
Nebraska
-
Omaha, Nebraska, 미국, 68198-5885
- Research Site
-
-
New York
-
New York, New York, 미국, 10028
- Research Site
-
Rochester, New York, 미국, 14642
- Research Site
-
-
North Carolina
-
Charlotte, North Carolina, 미국, 28207
- Research Site
-
Statesville, North Carolina, 미국, 28625
- Research Site
-
-
Ohio
-
Cleveland, Ohio, 미국, 44195
- Research Site
-
-
Oregon
-
Portland, Oregon, 미국, 97239
- Research Site
-
-
Rhode Island
-
Providence, Rhode Island, 미국, 02903
- Research Site
-
-
South Carolina
-
Charleston, South Carolina, 미국, 29425
- Research Site
-
-
Texas
-
Dallas, Texas, 미국, 75390-8843
- Research Site
-
-
Virginia
-
Charlottesville, Virginia, 미국, 22903
- Research Site
-
Roanoke, Virginia, 미국, 24016
- Research Site
-
-
-
-
-
Sofia, 불가리아, 1784
- Research Site
-
Sofia, 불가리아, 1463
- Research Site
-
Sofia, 불가리아, 1528
- Research Site
-
-
-
-
-
Belo Horizonte, 브라질, 30150-221
- Research Site
-
Porto Alegre, 브라질, 90035903
- Research Site
-
Rio de Janeiro, 브라질, 22470-220
- Research Site
-
Salvador, 브라질, 40150-150
- Research Site
-
São Paulo, 브라질, 05403-000
- Research Site
-
-
-
-
-
Belgrade, 세르비아, 11000
- Research Site
-
Kragujevac, 세르비아, 34000
- Research Site
-
-
-
-
-
Barcelona, 스페인, 8035
- Research Site
-
Barcelona, 스페인, 08025
- Research Site
-
Castellon, 스페인, 12004
- Research Site
-
Granada, 스페인, 18012
- Research Site
-
L'Hospitalet de Llobregat, 스페인, 08907
- Research Site
-
Las Palmas de Gran Canaria, 스페인, 35010
- Research Site
-
Madrid, 스페인, 28034
- Research Site
-
Madrid, 스페인, 28041
- Research Site
-
Madrid, 스페인, 28040
- Research Site
-
Madrid, 스페인, 28006
- Research Site
-
Majadahonda, 스페인, 28222
- Research Site
-
Salamanca, 스페인, 37007
- Research Site
-
Seville, 스페인, 41014
- Research Site
-
Valencia, 스페인, 46014
- Research Site
-
Valencia, 스페인, 46017
- Research Site
-
Vigo, 스페인, 36200
- Research Site
-
-
-
-
-
Košice, 슬로바키아, 04001
- Research Site
-
Piešťany, 슬로바키아, 92101
- Research Site
-
-
-
-
-
Ciudad de Buenos Aires, 아르헨티나, 1221
- Research Site
-
Córdoba, 아르헨티나, 5000
- Research Site
-
Córdoba, 아르헨티나, X5004BAL
- Research Site
-
Quilmes, 아르헨티나, 1878
- Research Site
-
San Miguel, 아르헨티나, 1663
- Research Site
-
-
-
-
-
Cambridge, 영국, CB2 0QQ
- Research Site
-
Leeds, 영국, LS2 9JT
- Research Site
-
London, 영국, NW1 2PG
- Research Site
-
London, 영국, SE5 9RS
- Research Site
-
London, 영국, SE1 7EH
- Research Site
-
London, 영국, NW3 2QG
- Research Site
-
Newcastle upon Tyne, 영국, NE1 4LP
- Research Site
-
-
-
-
-
Graz, 오스트리아, 8036
- Research Site
-
Innsbruck, 오스트리아, 6020
- Research Site
-
Linz, 오스트리아, 4020
- Research Site
-
Vienna, 오스트리아, 1130
- Research Site
-
-
-
-
-
Brescia, 이탈리아, 25123
- Research Site
-
Cona, 이탈리아, 44124
- Research Site
-
Florence, 이탈리아, 50121
- Research Site
-
Milan, 이탈리아, 20132
- Research Site
-
Naples, 이탈리아, 80138
- Research Site
-
Reggio Emilia, 이탈리아, 42123
- Research Site
-
Roma, 이탈리아, 00144
- Research Site
-
Rome, 이탈리아, 00168
- Research Site
-
-
-
-
-
Chūōku, 일본, 104-8560
- Research Site
-
Fukuoka, 일본, 812-8582
- Research Site
-
Kanazawa, 일본, 920-8641
- Research Site
-
Kita-gun, 일본, 761-0793
- Research Site
-
Nagoya, 일본, 457-8510
- Research Site
-
Nagoya, 일본, 467-8602
- Research Site
-
Wakayama, 일본, 641-8510
- Research Site
-
Yokohama, 일본, 232-0024
- Research Site
-
tabashi City, 일본, 173-8606
- Research Site
-
-
-
-
-
Changchun, 중국, 130021
- Research Site
-
Changsha, 중국, 410011
- Research Site
-
Chengdu, 중국, 610021
- Research Site
-
Chongqing, 중국, 400016
- Research Site
-
Dongguan, 중국, 523059
- Research Site
-
Guangzhou, 중국, 510120
- Research Site
-
Heilongjiang, 중국, 150086
- Research Site
-
Jinan, 중국, 250022
- Research Site
-
Shanghai, 중국, 200025
- Research Site
-
Shanghai, 중국, 200443
- Research Site
-
Shenzhen, 중국, 518053
- Research Site
-
Shenzhen, 중국, 518020
- Research Site
-
Shenzhen, 중국, 518052
- Research Site
-
Zhuzhou, 중국, 412007
- Research Site
-
Ürümqi, 중국, CN-830004
- Research Site
-
-
-
-
-
Osorno, 칠레, 200025
- Research Site
-
Santiago, 칠레, 7500571
- Research Site
-
Santiago, 칠레, 130021
- Research Site
-
-
-
-
British Columbia
-
Vancouver, British Columbia, 캐나다, V5Z 1M9
- Research Site
-
-
Ontario
-
Hamilton, Ontario, 캐나다, L8N 3Z5
- Research Site
-
Toronto, Ontario, 캐나다, M5T 2S8
- Research Site
-
-
-
-
-
Barranquilla, 콜롬비아, 080020
- Research Site
-
Bogotá, 콜롬비아, 110221
- Research Site
-
-
-
-
-
Bangkok, 태국, 10330
- Research Site
-
Bangkok, 태국, 10700
- Research Site
-
Hat Yai, 태국, 90110
- Research Site
-
Khlong Luang, 태국, 12120
- Research Site
-
Khon Kaen, 태국, 40002
- Research Site
-
-
-
-
-
Cordaleo, 터키 (Türkiye), 35575
- Research Site
-
Istanbul, 터키 (Türkiye), 34098
- Research Site
-
Kayseri, 터키 (Türkiye), 38039
- Research Site
-
Samsun, 터키 (Türkiye), 55270
- Research Site
-
-
-
-
-
Braga, 포르투갈, 4710-243
- Research Site
-
Lisbon, 포르투갈, 1649-035
- Research Site
-
Porto, 포르투갈, 4099-001
- Research Site
-
-
-
-
-
Katowice, 폴란드, 40-851
- Research Site
-
Kielce, 폴란드, 25-316
- Research Site
-
Ossy, 폴란드, 40-027
- Research Site
-
Rzeszów, 폴란드, 35-055
- Research Site
-
Warsaw, 폴란드, 02-637
- Research Site
-
-
-
-
-
Bois-Guillaume, 프랑스, 76031
- Research Site
-
Dijon, 프랑스, 21000
- Research Site
-
Lyon, 프랑스, 69437
- Research Site
-
Montivilliers, 프랑스, 76290
- Research Site
-
Nantes, 프랑스, 44000
- Research Site
-
Paris, 프랑스, 75010
- Research Site
-
Paris, 프랑스, 75014
- Research Site
-
Paris, 프랑스, 75013
- Research Site
-
Paris, 프랑스, 75970
- Research Site
-
Poitiers, 프랑스, 86000, FR
- Research Site
-
Toulouse, 프랑스, 31059
- Research Site
-
-
-
-
-
Iloilo City, 필리핀 제도, 5000
- Research Site
-
Lipa, 필리핀 제도, 4217
- Research Site
-
Manila, 필리핀 제도, 1000
- Research Site
-
-
-
-
-
Kogarah, 호주, 3168
- Research Site
-
Melbourne, 호주, 3004
- Research Site
-
Mitcham, 호주, 3132
- Research Site
-
Westmead, 호주, 2145
- Research Site
-
Woolloongabba, 호주, 04102
- Research Site
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Key inclusion criteria:
-
Participants must have a confirmed diagnosis of CLE. Diagnosis must be clinically and histologically confirmed with the following:
- CLASI-A total score ≥ 10 points at Screening and confirmed at randomization.
- Inadequate response or intolerant to antimalarial therapy.
-
Participants should have no medical history or signs or symptoms of active or prior tuberculosis infection (TB) and the same should reflect in chest radiograph or a chest CT scan result.
-
Contraceptive use by males and females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Key exclusion criteria:
- History or evidence of suicidal ideation.
- Severe or life-threatening Systemic lupus erythematosus (SLE).
- Active SLE or Sjögren's Syndrome.
- Any active skin conditions other than CLE that may interfere with the study.
- History of, or current diagnosis of, catastrophic antiphospholipid syndrome (APS).
- History of recurrent infection requiring hospitalization and IV antibiotics.
- COVID-19 infection.
- Any history of an anaphylactic reaction to human proteins, or monoclonal antibodies.
- At screening, if participants do not meet the eligibility criteria assessed based on laboratory test results e.g tests for total bilirubin, serum creatinine etc.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Anifrolumab
Participants will receive anifrolumab as a SC injection from Week 0/Day 1 up to Week 51. |
Anifrolumab will be provided as a solution for injection in accessorized pre-filled syringe (aPFS). |
|
위약 비교기: Placebo
Participants will receive placebo as a SC injection from Week 0/Day 1 up to Week 23. From Week 24 the participants will receive anifrolumab up to and including Week 51. |
Matching placebo solution for injection in aPFS. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of participants with a 70% reduction relative to baseline in the Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity (CLASI-A) score
기간: At Week 24
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. It consists of 2 separate scores: i) activity of the disease, and ii) measure of damage. The CLASI instrument will be used at each study visit to capture individual skin manifestation scores. CLASI-70 responder (Yes/No) is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder. |
At Week 24
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change from baseline in total CLASI-A score
기간: At Week 24
|
The CLASI-A is a validated index used for assessing the cutaneous lesions of SLE. |
At Week 24
|
|
Number of participants with CLASI-70 response
기간: At Week 12
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-70 responder is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder. |
At Week 12
|
|
Number of participants with ≥ 7-point reduction from baseline in CLASI-A total score
기간: At Week 12
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. A 7-point reduction CLASI-A is established as clinically meaningful improvement in disease for CLE and as being impactful for patients. |
At Week 12
|
|
Number of participants with CLASI-50 response
기간: At Week 12 and Week 24
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-50 responder is defined as a responder (yes/no) is defined as a participant who achieves at least a 50% reduction relative to baseline in CLASI-A score. Otherwise, the participant is a non-responder. |
At Week 12 and Week 24
|
|
Number of participants who are sustained CLASI-70 responders
기간: Up to Week 52
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-70 responder is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder. Amongst participants randomized to anifrolumab, the number of participants who maintained a CLASI-70 response from Week 24 up to Week 52 will be evaluated. |
Up to Week 52
|
|
Serum trough (pre-dose) concentrations of anifrolumab
기간: Double-blind: Pre-dose on Day 1 (Week 0), Weeks 1, 4, 12, 24; Open-label: Weeks 40, and 52 or early discontinuation visit [EDV] and follow-up visit (13 Weeks after last dose)
|
The Ctrough of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated. |
Double-blind: Pre-dose on Day 1 (Week 0), Weeks 1, 4, 12, 24; Open-label: Weeks 40, and 52 or early discontinuation visit [EDV] and follow-up visit (13 Weeks after last dose)
|
|
Number of participants with positive antidrug antibody
기간: Double-blind: Pre-dose on Day 1 (Week 0), Weeks 4, 12, and 24; Open-label: Pre-dose on Weeks 40, and 52 or EDV and follow-up visit (13 weeks after last dose)
|
The immunogenicity of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated. |
Double-blind: Pre-dose on Day 1 (Week 0), Weeks 4, 12, and 24; Open-label: Pre-dose on Weeks 40, and 52 or EDV and follow-up visit (13 weeks after last dose)
|
|
Percent change from baseline in suppression of the Interferon 21-gene
기간: Double-blind: Day 1 (Week 0), Week 1, 4, 12, and 24; Open-label; Week 40 and 52 or EDV and follow-up visit (13 weeks after last dose)
|
The pharmacodynamics of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated. |
Double-blind: Day 1 (Week 0), Week 1, 4, 12, and 24; Open-label; Week 40 and 52 or EDV and follow-up visit (13 weeks after last dose)
|
|
Change from baseline in Skindex-29+3 Symptom domain scores
기간: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. The instrument consists of 33 items, which are used to calculate 4 domains: Symptoms (7 items), Emotions (10 items), Functioning (12 items), and Lupus-specific (3 items). The remaining item asks the participants to rate how often they worry about side effects from treatment; however, this item is not used to calculate the domain scores. The response options are on a 5-point verbal rating scale, ranging from 1 (Never) to 5 (All the time). The instrument has a recall period of the previous 4 weeks. Each domain score ranges from 0 to 100 points, with higher scores indicating worse health-related quality of life. |
At Week 24
|
|
Change from baseline in Skindex-29+3 Emotion domain scores
기간: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. |
At Week 24
|
|
Change from baseline in Skindex-29+3 Function domain scores
기간: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. |
At Week 24
|
|
Change from baseline in Skindex-29+3 Lupus-Specific domain scores
기간: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. |
At Week 24
|
|
Change from baseline in Skindex-29+3 Total score
기간: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. |
At Week 24
|
|
Time from IP start date to CLASI-70 response.
기간: From Week 0/Day 1 up to Week 24
|
To assess the efficacy of anifrolumab compared with placebo on the onset of reduction in skin manifestations in participants with chronic and/or subacute CLE. |
From Week 0/Day 1 up to Week 24
|
|
Time from IP start date to CLASI-50 response.
기간: From Week 0/Day 1 up to Week 24
|
To assess the efficacy of anifrolumab compared with placebo on the onset of reduction in skin manifestations in participants with chronic and/or subacute CLE. |
From Week 0/Day 1 up to Week 24
|
기타 결과 측정
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of participants with adverse events
기간: Screening (up to and including 42 days before Day 1) until Safety Follow-up Period (12 weeks from Week 52/EDV)
|
To evaluate the safety and tolerability of anifrolumab compared with placebo in participants with CLE. |
Screening (up to and including 42 days before Day 1) until Safety Follow-up Period (12 weeks from Week 52/EDV)
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- D346BC00001
- 2021-003698-70 (EudraCT 번호)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
IPD 공유 기간
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD 공유 액세스 기준
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .